NFs were first tested as possible biomarkers by Rosengren et al., who detected an increase in cerebrospinal fluid (CSF) NF-light chain (NF-L) in patients with Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) compared to controls [1]. Here, NEFL is linked to Alzheimer disease.